Medy-Tox

Medytox is a medical-aesthetics-focused biopharmaceutical company built around two core pillars: botulinum toxin products and hyaluronic acid (HA) fillers.

Its flagship domestic products are MEDITOXIN, CORETOX, and INNOTOX, along with the next-generation toxin NEWLUX developed by a group affiliate, which is exported under names such as Neuronox to roughly 30 countries.

The filler business centers on the Neuramis brand, which is expanding sales in major overseas markets, alongside the dermocosmetics brand Nuraderm.

In 2025, the company received Korea's 40th domestically approved new drug designation for Nuviju (NUVIJU), a cholic-acid-based submental fat-reduction injectable that launched in March 2026, adding a new growth pillar.

The body-fat-reduction probiotic MT961 also received individually recognized functional ingredient approval and is preparing to enter the health-supplement market.

MT10109L, a non-animal-derived liquid-form toxin targeting the United States market, remains a key pipeline asset in preparation for an FDA Biologics License Application.

In the competitive landscape, Medytox competes with Hugel, the industry leader by combined domestic and export sales, as well as Pharma Research and Huons Medicare, among others, in the toxin and filler markets.

Production centers on the Osong Plant 2 and Plant 3, and NEWLUX capacity expanded with a newly added Building E at Plant 3 in addition to the existing Building B. The company is pursuing additional Neuronox manufacturing sites starting in Saudi Arabia and extending into Brazil and Colombia to broaden its export base.

Consolidated 2025 revenue rose to KRW 247.29 billion from KRW 228.62 billion in 2024, but operating profit declined to KRW 17.0 billion (a 6.9% operating margin) from KRW 20.35 billion (8.9% margin) the prior year, reflecting margin compression.

Net profit attributable to owners also slipped slightly to KRW 15.66 billion from KRW 16.07 billion.

Operating margin, which stood at 23.9% in 2022, fell sharply to 7.8% in 2023 and has remained in the mid-single digits through 2024 and 2025, marking a structurally different profitability profile from the earlier high-margin period.

On a quarterly basis, Q3 2025 revenue reached KRW 61.0 billion with operating profit of KRW 8.9 billion, but Q4 2025 swung to an operating loss of KRW 3.7 billion on revenue of KRW 60.7 billion.

Q1 2026 recovered to revenue of KRW 60.7 billion with operating profit of KRW 7.4 billion and net profit of KRW 7.8 billion, but in Q2 2026 revenue rose to KRW 68.7 billion while operating profit fell to KRW 4.8 billion and net profit fell to KRW 3.1 billion.

The Q2 2026 operating profit was characterized as an earnings shock, missing market consensus by more than 40%, and commission and fee expenses including legal costs reached KRW 33.7 billion in the first half, up 44.1% from KRW 23.3 billion a year earlier, equal to 2.8 times the first-half operating profit.

Korea Investment & Securities, in an August 12, 2026 report, attributed the weakness to higher cost of goods from periodic factory maintenance and increased marketing spend for the new product, and assigned a 'neutral' rating.

While the top-line growth trend has held, quarter-to-quarter earnings volatility increasingly hinges on the size of litigation-related expenses.

The domestic botulinum toxin and filler market is in a phase of simultaneous growth in aesthetic-procedure demand and export expansion.

On a combined domestic and export sales basis, Hugel remains the industry leader, while Medytox consolidates its position with a four-product toxin lineup spanning MEDITOXIN, CORETOX, INNOTOX, and NEWLUX, alongside the Neuramis filler line.

Competition in the toxin market is shifting from domestic share battles toward regulatory approvals in emerging markets across Asia, Europe, and Latin America, with NEWLUX having secured approvals in Thailand, Peru, Bolivia, the Dominican Republic, El Salvador, Panama, and Ukraine, among others.

Entry into advanced markets such as the United States still faces high regulatory hurdles, making the outcome of MT10109L's FDA approval process a key variable for the medium-to-long-term competitive landscape.

The strain and manufacturing-technology dispute with Daewoong Pharmaceutical illustrates industry-wide intellectual-property litigation risk, with the nine-year-old legal battle imposing direct cost burdens on both companies' earnings.

At the same time, some in the industry note that the spread of GLP-1 class obesity treatments, which can lead to skin laxity, may stimulate demand for aesthetic procedures.

Overall, the industry continues to grow, but individual company performance is increasingly differentiated by litigation outcomes, regulatory approvals, and new product success.

The company has stated plans to sustain growth in the second half through expanded Nuviju market penetration, strengthened academic programs for medical practitioners, and continued global market efforts.

NEWLUX export-country expansion is scheduled during 2026, and DB Financial Investment noted that additional Neuronox manufacturing sites, which began in Saudi Arabia, are spreading into Latin American countries such as Brazil and Colombia.

The body-fat-reduction supplement MT961 has received individually recognized functional ingredient approval and is being prepared for launch, while the FDA BLA refiling for MT10109L targeting the U.S. market is described as a project receiving the company's full effort.

In its value-up plan, the company set targets including maintaining an annual par-value dividend ratio of 200% or more in the near term, expanding dividends over the medium to long term, and introducing quarterly dividends.

That said, some in the market believe the new products' revenue contribution remains too small to meaningfully lift overall profitability in the short term.

The appellate case against Daewoong Pharmaceutical at the Seoul High Court has entered a new phase following the expanded damages claim, and the next hearing date and subsequent court proceedings warrant continued monitoring for their impact on earnings.